MX2017016863A - Metodo de tratamiento de tumores neuroendocrinos que sobreexpresan receptores de somatostatatina. - Google Patents

Metodo de tratamiento de tumores neuroendocrinos que sobreexpresan receptores de somatostatatina.

Info

Publication number
MX2017016863A
MX2017016863A MX2017016863A MX2017016863A MX2017016863A MX 2017016863 A MX2017016863 A MX 2017016863A MX 2017016863 A MX2017016863 A MX 2017016863A MX 2017016863 A MX2017016863 A MX 2017016863A MX 2017016863 A MX2017016863 A MX 2017016863A
Authority
MX
Mexico
Prior art keywords
treatment
over
express
receptors
neuroendocrine tumors
Prior art date
Application number
MX2017016863A
Other languages
English (en)
Inventor
BUONO Stefano
Lopera SIERRA Maribel
Original Assignee
Advanced Accelerator Applications
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Accelerator Applications filed Critical Advanced Accelerator Applications
Publication of MX2017016863A publication Critical patent/MX2017016863A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/083—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

La presente invención se refiere a métodos de tratamiento para cánceres que sobre expresan receptores de somatostatina. Específicamente, la invención proporciona una terapia combinada en la cual una combinación de Terapia con radionúclidos del receptor de péptido (PRRT, por sus siglas en inglés) y terapia inmuno oncológica (terapia I-O) se administra para el tratamiento de tumores neuroendócrinos.
MX2017016863A 2015-06-25 2016-06-24 Metodo de tratamiento de tumores neuroendocrinos que sobreexpresan receptores de somatostatatina. MX2017016863A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562176901P 2015-06-25 2015-06-25
PCT/IB2016/001089 WO2016207732A1 (en) 2015-06-25 2016-06-24 Method of treatment of neuroendocrine tumors that over-express somatostatatin receptors

Publications (1)

Publication Number Publication Date
MX2017016863A true MX2017016863A (es) 2018-09-06

Family

ID=56940095

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017016863A MX2017016863A (es) 2015-06-25 2016-06-24 Metodo de tratamiento de tumores neuroendocrinos que sobreexpresan receptores de somatostatatina.

Country Status (12)

Country Link
US (2) US20180185524A1 (es)
EP (2) EP3313888A1 (es)
JP (3) JP2018518526A (es)
KR (1) KR20180041623A (es)
CN (1) CN108137690A (es)
CA (1) CA2989266A1 (es)
CO (1) CO2017013041A2 (es)
HK (1) HK1254404A1 (es)
IL (1) IL256543B (es)
MX (1) MX2017016863A (es)
SG (1) SG10201913964QA (es)
WO (1) WO2016207732A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11633506B2 (en) 2016-07-18 2023-04-25 Wisconsin Alumni Research Foundation Using targeted radiotherapy (TRT) to drive anti-tumor immune response to immunotherapies
CN111565762A (zh) * 2017-11-10 2020-08-21 威斯康星校友研究基金会 使用靶向放射治疗(trt)来驱动对免疫疗法的抗肿瘤免疫反应
US10596276B2 (en) 2018-07-25 2020-03-24 Advanced Accelerator Applications (Italy) S.R.L. Stable, concentrated radionuclide complex solutions
CN112955188A (zh) * 2018-07-25 2021-06-11 先进加速器应用公司 治疗神经内分泌肿瘤的方法
WO2020021465A1 (en) 2018-07-25 2020-01-30 Advanced Accelerator Applications (Italy) S.R.L. Method of treatment of neuroendocrine tumors
US10596278B2 (en) 2018-07-25 2020-03-24 Advanced Accelerator Applications (Italy) S.R.L. Stable, concentrated radionuclide complex solutions
EP3693974A1 (en) * 2019-02-07 2020-08-12 Koninklijke Philips N.V. Identifying responsiveness to radio-immuno combination therapy
CN113616818B (zh) * 2020-05-06 2023-04-25 北京大学 一种用于肿瘤的靶向放射与免疫联合治疗的药物组合物
WO2022002022A1 (zh) * 2020-06-29 2022-01-06 北京拓界生物医药科技有限公司 一种放射性核素标记物及其应用
CN111840585B (zh) * 2020-07-20 2022-05-03 厦门大学 一种用于肿瘤免疫治疗的药物组合
TW202227143A (zh) 2020-08-27 2022-07-16 加拿大商探針開發暨商業化中心 放射性藥物及方法
US11541134B1 (en) 2021-08-02 2023-01-03 Rayzebio, Inc. Stabilized compositions of radionuclides and uses thereof
WO2023084445A1 (en) 2021-11-12 2023-05-19 Novartis Ag Combination therapy for treating lung cancer
WO2023208341A1 (en) 2022-04-27 2023-11-02 ITM Isotope Technologies Munich SE Combination treatment of small-cell lung cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830431A (en) 1995-06-07 1998-11-03 Mallinckrodt Medical, Inc. Radiolabeled peptide compositions for site-specific targeting
DK2769737T3 (en) * 2009-07-20 2017-07-24 Bristol Myers Squibb Co COMBINATION OF ANTI-CTLA4 ANTIBODY WITH ETOPOSIDE FOR SYNERGISTIC TREATMENT OF PROLIFERATIVE DISEASES
CA2791658C (en) * 2010-03-04 2019-10-01 Macrogenics, Inc. Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
CN104491890A (zh) * 2014-11-21 2015-04-08 北京肿瘤医院 放射性核素标记的新型生长抑素类似物分子探针及其应用

Also Published As

Publication number Publication date
US20220143227A1 (en) 2022-05-12
HK1254404A1 (zh) 2019-07-19
JP2023002792A (ja) 2023-01-10
IL256543B (en) 2022-01-01
JP2020040992A (ja) 2020-03-19
KR20180041623A (ko) 2018-04-24
IL256543A (en) 2018-02-28
CO2017013041A2 (es) 2018-03-28
EP4286008A2 (en) 2023-12-06
EP3313888A1 (en) 2018-05-02
WO2016207732A1 (en) 2016-12-29
CN108137690A (zh) 2018-06-08
SG10201913964QA (en) 2020-03-30
CA2989266A1 (en) 2016-12-29
EP4286008A3 (en) 2024-02-28
JP2018518526A (ja) 2018-07-12
US20180185524A1 (en) 2018-07-05

Similar Documents

Publication Publication Date Title
MX2017016863A (es) Metodo de tratamiento de tumores neuroendocrinos que sobreexpresan receptores de somatostatatina.
MX2018008426A (es) Combinaciones anti-egfr para tratar tumores.
AU2020267226B2 (en) Multispecific binding proteins targeting nkg2d, cd16. and trop2
AU2022259847B2 (en) AXL-specific antibody-drug conjugates for cancer treatment
MX2018008427A (es) Combinaciones anti-cd20 para tratar tumores.
MX2017013178A (es) Terapia de combinacion para cancer.
NZ753515A (en) Methods for treatment of cancer comprising tigit-binding agents
NZ738008A (en) Tigit-binding agents and uses thereof
PH12018502538A1 (en) Antibodies to alpha-synuclein and uses thereof
GEP20227440B (en) Anti-ilt4 antibodies and antigen-binding fragments
TW201613647A (en) Compounds and compositions for treating HER2 positive tumors
MX2019006331A (es) Métodos para tratar el cáncer usando anticuerpos anti-pd-l1 y antiandrógenos.
MX2021002970A (es) Proteinas de union a nkg2d, cd16 y un antigeno asociado a tumor.
MX2021010035A (es) Metodos para tratar canceres de mama metastasicos o localmente avanzados con antagonistas de union al eje de pd-1 y taxanos.
NZ725459A (en) Combination therapy for treating cancer with a recombinant poxvirus expressing a tumor antigen and an immune checkpoint molecule antagonist or agonist
GEP20217271B (en) Combination therapy for the treatment of cancer
IL240035B (en) A fusion protein containing a cd47 blocker and a trail receptor-binding polypeptide for the treatment of malignant diseases
MX2017004526A (es) Terapia combinada de anticuerpos biespecificos especificos para fap y dr5 y agentes quimioterapeuticos.
MX2015005252A (es) Metodo novedoso para tratar infarto cardiaco utilizando fragmento de hmgb1.
MX2016011114A (es) Composiciones y metodos para el tratamiento de tumores que sobreexpresan her2/neu.
MX344772B (es) Analogos de estilbeno y metodos para tratar cancer.
PH12017500853A1 (en) Cd44v6-derived cyclic peptides for treating cancers and angionesesis related diseases
PH12021551036A1 (en) Anti-liv1 immune cell cancer therapy
MX2019003722A (es) Composiciones inmunogénicas de tert y métodos de tratamiento que las utilizan.
MX2019009847A (es) Proteínas que se unen a cd123, nkg2d y cd16.